Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Eur J Surg Oncol. 2016 Dec 15;43(5):884–892. doi: 10.1016/j.ejso.2016.12.002

Figure 1. Targetable Pathways in HNSCC.

Figure 1

Currently FDA-approved targeted agents are limited to cetuximab (EGFR antibody), pembrolizumab and nivolumab (PD-1 antibodies). Additional targetable and commonly mutated pathways include other members of growth factor receptor families, Ras-MAPK and JAK/STAT downstream signaling pathways, PI3K, and downstream effectors of Notch1.